JP2023082171A5 - - Google Patents

Download PDF

Info

Publication number
JP2023082171A5
JP2023082171A5 JP2023060933A JP2023060933A JP2023082171A5 JP 2023082171 A5 JP2023082171 A5 JP 2023082171A5 JP 2023060933 A JP2023060933 A JP 2023060933A JP 2023060933 A JP2023060933 A JP 2023060933A JP 2023082171 A5 JP2023082171 A5 JP 2023082171A5
Authority
JP
Japan
Prior art keywords
optionally substituted
unit
subscript
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023060933A
Other languages
English (en)
Japanese (ja)
Other versions
JP7573679B2 (ja
JP2023082171A (ja
Filing date
Publication date
Priority claimed from JP2019503986A external-priority patent/JP7257951B2/ja
Application filed filed Critical
Publication of JP2023082171A publication Critical patent/JP2023082171A/ja
Publication of JP2023082171A5 publication Critical patent/JP2023082171A5/ja
Application granted granted Critical
Publication of JP7573679B2 publication Critical patent/JP7573679B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023060933A 2016-08-09 2023-04-04 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート Active JP7573679B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662372455P 2016-08-09 2016-08-09
US62/372,455 2016-08-09
JP2019503986A JP7257951B2 (ja) 2016-08-09 2017-08-09 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート
PCT/US2017/046157 WO2018031690A1 (en) 2016-08-09 2017-08-09 Drug conjugates with self-stabilizing linkers having improved physiochemical properties

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019503986A Division JP7257951B2 (ja) 2016-08-09 2017-08-09 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2023082171A JP2023082171A (ja) 2023-06-13
JP2023082171A5 true JP2023082171A5 (cg-RX-API-DMAC7.html) 2023-07-18
JP7573679B2 JP7573679B2 (ja) 2024-10-25

Family

ID=61162990

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503986A Active JP7257951B2 (ja) 2016-08-09 2017-08-09 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート
JP2023060933A Active JP7573679B2 (ja) 2016-08-09 2023-04-04 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019503986A Active JP7257951B2 (ja) 2016-08-09 2017-08-09 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート

Country Status (14)

Country Link
US (2) US11944689B2 (cg-RX-API-DMAC7.html)
EP (1) EP3496747A4 (cg-RX-API-DMAC7.html)
JP (2) JP7257951B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240010534A (cg-RX-API-DMAC7.html)
CN (1) CN109562152B (cg-RX-API-DMAC7.html)
AU (2) AU2017310436B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019001945A2 (cg-RX-API-DMAC7.html)
EA (1) EA201990470A1 (cg-RX-API-DMAC7.html)
IL (1) IL264453A (cg-RX-API-DMAC7.html)
MA (1) MA45945A (cg-RX-API-DMAC7.html)
MX (2) MX2019001302A (cg-RX-API-DMAC7.html)
SG (1) SG11201900699QA (cg-RX-API-DMAC7.html)
TW (2) TW202500191A (cg-RX-API-DMAC7.html)
WO (1) WO2018031690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240156969A1 (en) * 2015-12-04 2024-05-16 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
GB201820864D0 (en) * 2018-12-20 2019-02-06 J A Kemp Antibody-drug conjugates
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
KR102501394B1 (ko) * 2019-05-02 2023-02-21 주식회사 레고켐 바이오사이언스 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
US20220226496A1 (en) * 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
WO2020254602A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
AU2020482800B2 (en) * 2020-12-23 2025-08-21 Genequantum Healthcare (Suzhou) Co., Ltd. Novel isomeric compounds comprising a ring-opened thiosuccinimide group, an oligopeptide fragment and a chiral moiety
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CN122080121A (zh) 2023-03-22 2026-05-26 映恩生物科技(上海)有限公司 连接子及其在配体药物偶联物中的应用
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
KR20240159448A (ko) 2023-04-28 2024-11-05 주식회사 에이비켐바이오 균일한 dar를 갖는 신규한 항체-약물 중합체의 제조방법
KR20240159447A (ko) 2023-04-28 2024-11-05 주식회사 에이비켐바이오 말레이미드 함유 링커-페이로드 접합체
KR20250074353A (ko) 2023-11-20 2025-05-27 주식회사 에이비켐바이오 높은 dar를 갖는 신규한 항체-약물 중합체, 이의 제조방법 및 이의 용도
EP4735048A1 (en) * 2023-06-29 2026-05-06 Beone Medicines I GmbH Bioactive conjugates, preparation method and use thereof
TW202525344A (zh) * 2023-08-15 2025-07-01 瑞典商阿斯特捷利康公司 包含可切割連接子的軛合物
JPWO2025058000A1 (cg-RX-API-DMAC7.html) 2023-09-13 2025-03-20
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
TW202547866A (zh) 2024-01-10 2025-12-16 丹麥商珍美寶股份有限公司 Slitrk6結合劑、其共軛物及使用彼之方法
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
JPS6423340U (cg-RX-API-DMAC7.html) 1987-08-03 1989-02-07
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5091542A (en) 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
JPH07508550A (ja) 1992-07-01 1995-09-21 アクゾ ノーベル ナムローゼ フェンノートシャップ ポリフェニレンエーテル樹脂組成物を変性する方法
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US5973166A (en) 1998-03-02 1999-10-26 The Dexter Corporation Method for the preparation of maleimides
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US7125844B2 (en) 2002-01-03 2006-10-24 Migenix Inc. Dab9 derivatives of lipopeptide antibiotics and methods of making and using the same
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
KR101031206B1 (ko) * 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
RU2448117C2 (ru) 2003-11-06 2012-04-20 Сиэтл Дженетикс, Инк. Монометилвалиновые соединения, способные образовывать конъюгаты с лигандами
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
UA85716C2 (en) * 2004-05-19 2009-02-25 Медарекс, Инк. Chemical linkers and their conjugates
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20060292616A1 (en) * 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
DK1813614T3 (da) 2006-01-25 2012-01-23 Sanofi Sa Cytotoksiske midler, der omfatter nye tomaymycinderivater
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
CA3014224C (en) 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
JP6121906B2 (ja) 2010-10-22 2017-04-26 シアトル ジェネティクス,インコーポレーテッド アウリスタチン系抗体薬物複合体とPI3K−AKTmTOR経路インヒビターの間の相乗効果
PT3156420T (pt) 2010-12-06 2019-05-27 Seattle Genetics Inc Anticorpos humanizados a liv-1 e seu uso para tratar o cancro
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
CH706603B1 (de) 2011-08-03 2016-08-31 Ophthametrics Ag Hrm Man & Treuhand Ag Aufnahmevorrichtung zur Aufnahme einer Netzhaut eines Auges sowie Aufnahmeverfahren.
BR112014013526A8 (pt) * 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
RU2582259C2 (ru) * 2012-02-24 2016-04-20 Алтеоген Инк. Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения
CN104822656B (zh) 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
US9504756B2 (en) * 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP2968591A1 (en) 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
EP3107557B1 (en) 2014-02-17 2021-06-09 Seagen Inc. Hydrophilic antibody-drug conjugates
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos

Similar Documents

Publication Publication Date Title
US20240307561A1 (en) Radiolabeled parp inhibitor conjugates for cancer treatment
Chytil et al. HPMA copolymer–drug conjugates with controlled tumor‐specific drug release
JP2019524759A5 (cg-RX-API-DMAC7.html)
AU2020210919B2 (en) Glycoside-containing peptide linkers for antibody-drug conjugates
ES2918425T3 (es) Conjugados de anticuerpo-fármaco
JP6193433B2 (ja) Cc−1065類似体の新規の複合体および二官能性リンカー
ES2983109T3 (es) Conjugados enlazadores autoestabilizantes
ES2615268T3 (es) Compuestos de enediino, conjugados de los mismos y usos y métodos para ello
RU2006144958A (ru) Химические линкеры и их конъюгаты
AU2018241840A1 (en) HDAC inhibitors-based antibody drug conjugates (ADCs) and use in therapy
JP2023119064A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP2017504606A5 (cg-RX-API-DMAC7.html)
RU2010149608A (ru) Антиангиогенные соединения
AU2013302270A1 (en) Peptide-dendrimer conjugates and uses thereof
CA2908993C (en) Metap2 inhibitors and methods of treating obesity
CA3149263A1 (en) Targeted dendrimer conjugates
ES2923853T3 (es) Materiales y métodos relacionados con conectores para su uso en productos conjugados de proteína y fármaco
Shankar et al. Cathepsin B degradable star-shaped peptidic macromolecules for delivery of 2-methoxyestradiol
JP2023129495A5 (cg-RX-API-DMAC7.html)
JP2021513990A5 (cg-RX-API-DMAC7.html)
JP2020517599A5 (cg-RX-API-DMAC7.html)
CA3076289A1 (en) Psma-targeting amanitin conjugates
ES2902179T3 (es) Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
JP2024528719A (ja) コンジュゲート化試薬及びそのコンジュゲート
Chen et al. Improved protein toxin delivery based on ATTEMPTS systems